Newsroom

Blog

Talking Cancer: Conversations with Trailblazers, Advocates, Patients, and Medical Ambassadors

Interview with Patient Advocate Marcia Horn, CEO, ICAN Network

Madhushree Ghosh

Read More
Written By:
MadhuGhosh.jpg
Madhu Ghosh

Precision Medicine

Precision medicine reduces unnecessary risks to patients including hazardous side effects as well as ineffective treatments (“trial and error” medicine).

Read More
Written By:
JamesYen.jpg
James Yen

Genomics in Precision Medicine

We often hear “Don’t take anything personally”. However, that is not the case in terms of precision medicine. In 2015, the U.S. government launched the "Precision Medicine Initiative".

Read More
Written By:
QinqinZha.jpg
Qinqin Zha

Talking Cancer: Conversations with Trailblazers, Advocates, Patients and Medical Ambassadors

As a premier reference lab and global pharma services organization that runs over a million oncology tests annually, NeoGenomics Laboratories, Inc.

Read More
Written By:
MadhuGhosh.jpg
Madhu Ghosh

Trends – Epigenetic Biomarkers

In the oncology biomarker field, there are obvious trends in technology and markers as well as testing strategies.

Read More

Jemperli blog post - please share your thoughts!

We were glad to see FDA’s combined approval for GSK’s Jemperli (dostarlimab) and Ventana’s MMR RxDx for recurrent or advanced endometrial cancer back in April.

Read More
Written By:
scottreid.jpg
Scott Reid

Biomarker Types and CDx Biomarkers

The field of precision medicine is rooted in biomarker guided therapy. These biomarkers come in various forms as well as are categorized depending on use cases.

Read More
Written By:
JamesYen.jpg
James Yen

Liquid Biopsies

Despite the terminology “liquid biopsies” (LBx) becoming common place in diagnostic lexicon, as a routine clinical technology, LBx is still very much in its infancy.

Read More
Written By:
JamesYen.jpg
James Yen

Contact Us To Get Started!

Work with us – your premier oncology partner – to optimize cancer care for patients